Institution
Indiana University
Education•Bloomington, Indiana, United States•
About: Indiana University is a education organization based out in Bloomington, Indiana, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 64480 authors who have published 150058 publications receiving 6392902 citations. The organization is also known as: Indiana University system & indiana.edu.
Topics: Population, Poison control, Context (language use), Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The research examines an unobtrusive measure of racial attitudes based on the evaluations that are automatically activated from memory on the presentation of Black versus White faces and the status of the Modern Racism Scale (MRS).
Abstract: The research examines an unobtrusive measure of racial attitudes based on the evaluations that are automatically activated from memory on the presentation of Black versus White faces. Study 1, which concerned the technique's validity, obtained different attitude estimates for Black and White participants and also revealed that the variability among White participants was predictive of other race-related judgments and behavior. Study 2 concerned the lack of correspondence between the unobtrusive estimates and Modern Racism Scale (MRS) scores. The reactivity of the MRS was demonstrated in Study 3. Study 4 observed an interaction between the unobtrusive estimates and an individual difference in motivation to control prejudiced reactions when predicting MRS scores. The theoretical implications of the findings for consideration of automatic and controlled components of racial prejudice are discussed, as is the status of the MRS.
2,215 citations
••
TL;DR: The chromosomal localization of the Huntington's disease gene is the first step in using recombinant DNA technology to identify the primary genetic defect in this disorder.
Abstract: Family studies show that the Huntington's disease gene is linked to a polymorphic DNA marker that maps to human chromosome 4. The chromosomal localization of the Huntington's disease gene is the first step in using recombinant DNA technology to identify the primary genetic defect in this disorder.
2,211 citations
••
TL;DR: Attitude toward the ad (Aad) has been postulated to be a causal mediating variable in the process through which advertising influences brand attitudes and purchase intentions in this paper.
Abstract: Attitude toward the ad (Aad) has been postulated to be a causal mediating variable in the process through which advertising influences brand attitudes and purchase intentions. Previous conceptual a...
2,208 citations
••
TL;DR: It is shown that the Akt serine–threonine kinase is involved in the activation of NF-κB by tumour necrosis factor (TNF), and that Akt is part of a signalling pathway that is necessary for inducing key immune and inflammatory responses.
Abstract: Activation of the nuclear transcription factor NF-kappaB by inflammatory cytokines requires the successive action of NF-kappaB-inducing kinase (NIK) and an IKB-kinase (IKK) complex composed of IKKalpha and IKKbeta. Here we show that the Akt serine-threonine kinase is involved in the activation of NF-kappaB by tumour necrosis factor (TNF). TNF activates phosphatidylinositol-3-OH kinase (PI(3)K) and its downstream target Akt (protein kinase B). Wortmannin (a PI(3)K inhibitor), dominant-negative PI(3)K or kinase-dead Akt inhibits TNF-mediated NF-kappaB activation. Constitutively active Akt induces NF-kappaB activity and this effect is blocked by dominant-negative NIK. Conversely, NIK activates NF-kappaB and this is blocked by kinase-dead Akt. Thus, both Akt and NIK are necessary for TNF activation of NF-kappaB. Akt mediates IKKalpha phosphorylation at threonine 23. Mutation of this amino acid blocks phosphorylation by Akt or TNF and activation of NF-kappaB. These findings indicate that Akt is part of a signalling pathway that is necessary for inducing key immune and inflammatory responses.
2,205 citations
••
University of Texas Southwestern Medical Center1, Radiation Therapy Oncology Group2, Thomas Jefferson University3, Washington University in St. Louis4, Indiana University5, Princess Margaret Cancer Centre6, Cleveland Clinic7, Dartmouth College8, University of Wisconsin-Madison9, Medical College of Wisconsin10
TL;DR: Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.
Abstract: Context Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30%-40%) and a high rate of mortality (3-year survival, 20%-35%) with current management. Objective To evaluate the toxicity and efficacy of stereotactic body radiation therapy in a high-risk population of patients with early stage but medically inoperable lung cancer. Design, Setting, and Patients Phase 2 North American multicenter study of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non–small cell tumors (measuring Main Outcome Measures The primary end point was 2-year actuarial primary tumor control; secondary end points were disease-free survival (ie, primary tumor, involved lobe, regional, and disseminated recurrence), treatment-related toxicity, and overall survival. Results A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1 tumors and 11 patients with T2 tumors) with a median follow-up of 34.4 months (range, 4.8-49.9 months). Only 1 patient had a primary tumor failure; the estimated 3-year primary tumor control rate was 97.6% (95% confidence interval [CI], 84.3%-99.7%). Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6% (95% CI, 76.0%-96.5%). Two patients experienced regional failure; the local-regional control rate was 87.2% (95% CI, 71.0%-94.7%). Eleven patients experienced disseminated recurrence; the 3-year rate of disseminated failure was 22.1% (95% CI, 12.3%-37.8%). The rates for disease-free survival and overall survival at 3 years were 48.3% (95% CI, 34.4%-60.8%) and 55.8% (95% CI, 41.6%-67.9%), respectively. The median overall survival was 48.1 months (95% CI, 29.6 months to not reached). Protocol-specified treatment-related grade 3 adverse events were reported in 7 patients (12.7%; 95% CI, 9.6%-15.8%); grade 4 adverse events were reported in 2 patients (3.6%; 95% CI, 2.7%-4.5%). No grade 5 adverse events were reported. Conclusion Patients with inoperable non–small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.
2,202 citations
Authors
Showing all 64884 results
Name | H-index | Papers | Citations |
---|---|---|---|
Frank B. Hu | 250 | 1675 | 253464 |
Stuart H. Orkin | 186 | 715 | 112182 |
Bruce M. Spiegelman | 179 | 434 | 158009 |
David R. Williams | 178 | 2034 | 138789 |
D. M. Strom | 176 | 3167 | 194314 |
Markus Antonietti | 176 | 1068 | 127235 |
Lei Jiang | 170 | 2244 | 135205 |
Brenda W.J.H. Penninx | 170 | 1139 | 119082 |
Nahum Sonenberg | 167 | 647 | 104053 |
Carl W. Cotman | 165 | 809 | 105323 |
Yang Yang | 164 | 2704 | 144071 |
Jaakko Kaprio | 163 | 1532 | 126320 |
Ralph A. DeFronzo | 160 | 759 | 132993 |
Gavin Davies | 159 | 2036 | 149835 |
Tyler Jacks | 158 | 463 | 115172 |